MRNA vs. BIIB, GILD, BNTX, ARGX, NBIX, TECH, QGEN, RGEN, CRSP, and DNLI
Should you be buying Moderna stock or one of its competitors? The main competitors of Moderna include Biogen (BIIB), Gilead Sciences (GILD), BioNTech (BNTX), argenx (ARGX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Biogen (NASDAQ:BIIB) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
87.9% of Biogen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 15.7% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Biogen received 1580 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 71.91% of users gave Biogen an outperform vote while only 57.77% of users gave Moderna an outperform vote.
Biogen has a net margin of 12.07% compared to Biogen's net margin of -115.82%. Moderna's return on equity of 14.83% beat Biogen's return on equity.
Biogen has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
In the previous week, Biogen had 5 more articles in the media than Moderna. MarketBeat recorded 34 mentions for Biogen and 29 mentions for Moderna. Biogen's average media sentiment score of 0.64 beat Moderna's score of 0.31 indicating that Moderna is being referred to more favorably in the news media.
Biogen currently has a consensus price target of $288.46, suggesting a potential upside of 31.84%. Moderna has a consensus price target of $126.46, suggesting a potential downside of 21.84%. Given Moderna's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Moderna.
Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Summary
Biogen beats Moderna on 14 of the 18 factors compared between the two stocks.
Get Moderna News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
